キャンディン系抗真菌薬ミカファンギン

• 池田 文昭

  アステラス製薬株式会社 育薬研究所

書誌事項

タイトル別名

• Antifungal Activity and Clinical Efficacy of Micafungin (Funguard).

抄録

Micafungin (MCFG) is a new lipopeptide antifungal agent of the echinocandin class. MCFG inhibits 1, 3-β-D-glucan synthesis in C. albicans and A. fumigatus in a non-competitive manner, and has antifungal activity against both Aspergillus and Candida species. In neutropenic mouse models of disseminated candidiasis and pulmonary aspergillosis, the efficacy of MCFG was superior to that of fluconazole and itraconazole, but comparable to that of amphotericin B.<br>The efficacy and safety of MCFG were investigated in 70 patients with deep-seated mycosis caused by Candida and Aspergillus species. The overall clinical response rates were 57.1% in aspergillosis and 78.6% in candidiasis. The incidence of adverse events related to micafungin was 17.9%, and there was no dose-related occurrence of any adverse events. The results from this study indicated that micafungin was effective in aspergillosis and candidiasis, with no tolerability problems.

収録刊行物

• 日本医真菌学会雑誌

  日本医真菌学会雑誌 46 (4), 217-222, 2005

  日本医真菌学会

キーワード

• ミカファンギンナトリウム
• キャンディン系抗真菌薬
• 1,3-β-D-グルカンシンターゼ
• カンジダ症
• アスペルギルス症

詳細情報

• CRID: 1390282679189051264
• NII論文ID: 130003672134
• NII論文ID: 10017083880
• NII書誌ID: AN10166867
• DOI: 10.3314/jjmm.46.217
• COI: 1:CAS:528:DC%2BD28Xkt1aqtg%3D%3D
• ISSN: 18820476
• ISSN: 09164804
• PubMed: 16282962
• Web Site: https://search.jamas.or.jp/link/ui/2006220005
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可